Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06086288 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)(PANDORA) | not yet recruiting | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER |
| 1 |
| Oct 17, 2023 |
| clinicaltrials |
| NCT02608411 | TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)(TIMES) | terminated | Phase 2 | 5 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT06070740 | First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | recruiting | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05228496 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 3 | Kartos Therapeutics, Inc.INDUSTRY | 7 | Aug 16, 2023 | clinicaltrials |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02267603 | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT05896059 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT02687958 | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | unknown | Phase 2 | 30 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT01440816 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer(MCC) | completed | Phase 2 | 15 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 4 | Xencor, Inc.INDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | terminated | Phase 2 | 9 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05668767 | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | unknown | Phase 2 | 20 | Beijing Chest HospitalOTHER | 0 | Dec 30, 2022 | clinicaltrials |
| NCT03079440 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT01013779 | Merkel Positron Emission Tomography (PET) Protocol(MP3) | completed | Phase 2 | 43 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 22 | Ludwig Institute for Cancer ResearchOTHER | 5 | Oct 25, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02205515 | An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis(EBRT) | completed | Phase 1 / Phase 2 | 17 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05484583 | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | not yet recruiting | Phase 2 | 58 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT04525638 | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | unknown | Phase 2 | 30 | Fundación de investigación HMOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2023source: clinicaltrials